Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Reports $17M in Revenues from Roche

NEW YORK, April 21 (GenomeWeb News) - CombiMatrix reported $17.6 million in revenues in the first quarter, with $17.3 million of that coming in recognition of deferred contract revenues from a research and development agreement with Roche.

 

CombiMatrix is the life sciences unit of Newport Beach, Calif., based Acacia Research, which issued its first-quarter financial report today, including results for its Mulkiteo, Wash.-based subsidiary that trades on the Nasdaq exchange under the symbol CBMX.

 

CombiMatrix said that it completed an R&D agreement with Roche that included the development of a microarray platform, the MatrixArray.

 

CombiMatrix's first-quarter receipts also included $217,000 in contract revenue from a $5.9 million contract with the US Department of Defense to develop a biowarfare detection technology. The company reported revenues of $216,000 in the first quarter of 2003.

 

CombiMatrix had a net income of $12 million for the quarter, compared to a loss of $5.1 million for the year-ago period.

 

The company spent $1.5 million on research and development in the period, compared to $2.3 million for the year-ago quarter.

 

Cash, cash equivalents, and short-term investments on hand totaled $18.4 million as of March 31, compared to $17.3 million as of Dec. 31.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.